RESUMEN
BACKGROUND: Tailoring effective strategies for cancer pain management requires a careful analysis of multiple factors that influence pain phenomena and, ultimately, guide the therapy. While there is a wealth of research on automatic pain assessment (APA), its integration with clinical data remains inadequately explored. This study aimed to address the potential correlations between subjective and APA-derived objectives variables in a cohort of cancer patients. METHODS: A multidimensional statistical approach was employed. Demographic, clinical, and pain-related variables were examined. Objective measures included electrodermal activity (EDA) and electrocardiogram (ECG) signals. Sensitivity analysis, multiple factorial analysis (MFA), hierarchical clustering on principal components (HCPC), and multivariable regression were used for data analysis. RESULTS: The study analyzed data from 64 cancer patients. MFA revealed correlations between pain intensity, type, Eastern Cooperative Oncology Group Performance status (ECOG), opioids, and metastases. Clustering identified three distinct patient groups based on pain characteristics, treatments, and ECOG. Multivariable regression analysis showed associations between pain intensity, ECOG, type of breakthrough cancer pain, and opioid dosages. The analyses failed to find a correlation between subjective and objective pain variables. CONCLUSIONS: The reported pain perception is unrelated to the objective variables of APA. An in-depth investigation of APA is required to understand the variables to be studied, the operational modalities, and above all, strategies for appropriate integration with data obtained from self-reporting. TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov, number (NCT04726228), registered 27 January 2021, https://classic. CLINICALTRIALS: gov/ct2/show/NCT04726228?term=nct04726228&draw=2&rank=1.
Asunto(s)
Dolor en Cáncer , Dimensión del Dolor , Humanos , Masculino , Femenino , Dolor en Cáncer/diagnóstico , Persona de Mediana Edad , Dimensión del Dolor/métodos , Anciano , Adulto , Respuesta Galvánica de la Piel/fisiología , Electrocardiografía/métodos , Anciano de 80 o más Años , Manejo del Dolor/métodos , Manejo del Dolor/normas , Estudios de CohortesRESUMEN
BACKGROUND: Despite recent improvements in cancer detection and survival rates, managing cancer-related pain remains a significant challenge. Compared to neuropathic and inflammatory pain conditions, cancer pain mechanisms are poorly understood, despite pain being one of the most feared symptoms by cancer patients and significantly impairing their quality of life, daily activities, and social interactions. The objective of this work was to select a panel of biomarkers of central pain processing and modulation and assess their ability to predict chronic pain in patients with cancer using predictive artificial intelligence (AI) algorithms. METHODS: We will perform a prospective longitudinal cohort, multicentric study involving 450 patients with a recent cancer diagnosis. These patients will undergo an in-person assessment at three different time points: pretreatment, 6 months, and 12 months after the first visit. All patients will be assessed through demographic and clinical questionnaires and self-report measures, quantitative sensory testing (QST), and electroencephalography (EEG) evaluations. We will select the variables that best predict the future occurrence of pain using a comprehensive approach that includes clinical, psychosocial, and neurophysiological variables. DISCUSSION: This study aimed to provide evidence regarding the links between poor pain modulation mechanisms at precancer treatment in patients who will later develop chronic pain and to clarify the role of treatment modality (modulated by age, sex and type of cancer) on pain. As a final output, we expect to develop a predictive tool based on AI that can contribute to the anticipation of the future occurrence of pain and help in therapeutic decision making.
Asunto(s)
Dolor en Cáncer , Dolor Crónico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inteligencia Artificial , Biomarcadores , Dolor en Cáncer/diagnóstico , Dolor Crónico/diagnóstico , Dolor Crónico/etiología , Electroencefalografía , Estudios Longitudinales , Neoplasias/complicaciones , Dimensión del Dolor/métodos , Estudios Prospectivos , Calidad de Vida , Estudios Multicéntricos como AsuntoRESUMEN
BACKGROUND: Opioid use prior to cancer diagnosis increases the likelihood of long-term use during survivorship, however, patterns of use before and after diagnosis are not understood. METHODS: We used population-based dispensing data linked with cancer and death notifications to identify two cohorts of adults residing in New South Wales initiating opioids within 24 months prior to a first cancer diagnosed between 2014 and 2016: 'survivors' (alive 24 months following diagnosis) and 'decedents' (died within 24 months). We used group-based trajectory modelling to identify trajectories of monthly opioid dispensings and dispensed oral morphine equivalent milligrams (OMEmg) during the 24 months before/after cancer diagnosis. RESULTS: There were 21,843 survivors with four prediagnosis opioid dispensing trajectories: infrequent (58% of the cohort), late increasing (26%), moderate (10%), and sustained dispensing (6%). We observed an overall increase in dispensed OMEmg of 83 OMEmg (95% CI: 76-91) during the month of diagnosis, with strong opioid formulations comprising most treatment postdiagnosis. Within each prediagnosis opioid trajectory group, we observed five to six postdiagnosis trajectory groups, including no opioid dispensing. Moderate and sustained prediagnosis groups had large proportions of people continuing or increasing opioid dispensing after diagnosis, while small proportions discontinued opioid treatment. We observed similar trajectories in the decedent cohort. CONCLUSIONS: There is considerable heterogeneity in opioid use before and after cancer diagnosis. Our findings suggest noncancer factors drive a significant proportion of postdiagnosis opioid use, but use increased significantly from the month of cancer diagnosis and never returned to prediagnosis levels.
Asunto(s)
Analgésicos Opioides , Dolor en Cáncer , Neoplasias , Humanos , Masculino , Analgésicos Opioides/uso terapéutico , Femenino , Persona de Mediana Edad , Anciano , Estudios de Cohortes , Neoplasias/tratamiento farmacológico , Nueva Gales del Sur/epidemiología , Dolor en Cáncer/tratamiento farmacológico , Dolor en Cáncer/diagnóstico , Adulto , Supervivientes de Cáncer , Anciano de 80 o más Años , Adulto JovenRESUMEN
PURPOSE: To retrospectively study the therapeutic effect and safety performance of the combination strategies of the computed tomography (CT)-guided microwave ablation (MWA) and percutaneous vertebroplasty (PVP) as a treatment for painful non-small cell lung cancer (NSCLC) with spinal metastases. MATERIALS AND METHODS: A retrospective review included 71 patients with 109 vertebral metastases who underwent microwave ablation combined with percutaneous vertebroplasty by the image-guided and real-time temperature monitoring. Treatment efficacy was determined by comparing visual analog scale (VAS) scores, daily morphine equivalent opioid consumption, and Oswestry Disability Index (ODI) scores before treatment and during the follow-up period. RESULTS: Technical success was achieved in all patients. The mean pre-procedure VAS score and morphine doses were 6.6 ± 1.8 (4-10) and 137.2 ± 38.7 (40-200) mg, respectively. The mean VAS scores and daily morphine doses at 24 h and 1, 4, 12, and 24 weeks postoperatively were 3.3 ± 1.9 and 73.5 ± 39.4 mg; 2.2 ± 1.5 and 40.2 ± 29.8 mg; 1.7 ± 1.2 and 31.3 ± 23.6 mg; 1.4 ± 1.1 and 27.3 ± 21.4 mg; and 1.3 ± 1.1 and 24.8 ± 21.0 mg, respectively (all P < 0.001). ODI scores significantly decreased (P < 0.05). Minor cement leakage occurred in 51 cases (46.8%), with one patient having a grade 3 neural injury. No local tumor progression was observed by follow-up imaging. CONCLUSIONS: MWA combined with PVP can significantly relieve pain and improve patients' quality of life, which implied this is an effective treatment option for painful NSCLC with spinal metastases. Additionally, its efficacy should be further verified through the mid- and long-term studies.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Microondas , Neoplasias de la Columna Vertebral , Vertebroplastia , Humanos , Masculino , Femenino , Vertebroplastia/métodos , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/terapia , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Carcinoma de Pulmón de Células no Pequeñas/secundario , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/terapia , Persona de Mediana Edad , Microondas/uso terapéutico , Neoplasias de la Columna Vertebral/secundario , Neoplasias de la Columna Vertebral/terapia , Neoplasias de la Columna Vertebral/complicaciones , Anciano , Estudios Retrospectivos , Resultado del Tratamiento , Terapia Combinada/métodos , Dimensión del Dolor , Tomografía Computarizada por Rayos X , Adulto , Dolor en Cáncer/etiología , Dolor en Cáncer/terapia , Dolor en Cáncer/diagnóstico , Anciano de 80 o más Años , Manejo del Dolor/métodos , Estudios de SeguimientoRESUMEN
As one of the most common complications of cancer or its treatment, cancer-related pain can negatively affect the functional status and quality of life of patients. Pain management for cancer patients in China started later than that in developed countries. After 30 years of efforts by health authorities and medical professionals, cancer pain management in China has made great progress. However, with the accelerated aging of the Chinese population, the increasing incidence of cancer, the prolonged survival of cancer patients, and the strengthening of people's expectations for high-quality life, there is still a gap between the development level of cancer pain management in China and the actual health needs of cancer patients. This article provides a comprehensive overview of the current state and future challenges facing the integrated management of cancer pain in China. Simultaneously, it offers a prospective outlook on future developments, thereby furnishing vital information for professionals engaged in the field of cancer pain management.
Asunto(s)
Dolor en Cáncer , Neoplasias , Humanos , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/terapia , Calidad de Vida , Neoplasias/complicaciones , Manejo del Dolor , Envejecimiento , ChinaRESUMEN
Currently, the treatment of cancer pain in China mainly follows the three-step pain relief principles formulated by the World Health Organization. As research on subarachnoid drug diffusion has intensified, intrathecal drug delivery has been gradually applied in the treatment of diseases, and improved analgesia can be achieved via the continuous infusion of small doses of morphine-derived drugs. This method can not only effectively relieve pain and enhance quality of life but also significantly reduce the incidence of nausea, vomiting, constipation, and other adverse reactions caused by the long-term intensive use of drugs in patients with cancer pain. This study summarizes the development of the intrathecal drug-infusion system for treating cancer pain in patients with advanced cancer and describes the drugs used, the advantages in pain treatment, and key nursing factors before and after device placement to provide a basis for alleviating pain in patients with cancer.
Asunto(s)
Dolor en Cáncer , Neoplasias , Humanos , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/tratamiento farmacológico , Dolor en Cáncer/inducido químicamente , Calidad de Vida , Dolor/diagnóstico , Dolor/tratamiento farmacológico , Dolor/etiología , Morfina/efectos adversos , Sistemas de Liberación de Medicamentos/métodos , Inyecciones Espinales , Analgésicos Opioides/efectos adversos , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Neoplasias/inducido químicamenteRESUMEN
OBJECTIVES: To understand individual prescribing and associated costs in patients managed with the Edinburgh Pain Assessment and management Tool (EPAT). METHODS: The EPAT study was a two-arm parallel group cluster randomised (1:1) trial, including 19 UK cancer centres. Study outcome assessments, including pain levels, analgesia and non-pharmacological and anaesthetic interventions, collected at baseline, 3-5 days and, if applicable, 7-10 days after admission. Costs calculated for inpatient length of stay (LoS), medications and complex pain interventions. Analysis accounted for the clustered nature of the trial design. In this post-hoc analysis, healthcare utilisation and costs are presented descriptively. PARTICIPANTS: 10 centres randomised to EPAT (487 patients) and 9 (449 patients) to usual care (UC). MAIN OUTCOME MEASURES: Pharmacological and non-pharmacological management, complex pain interventions, length of hospital stay and costs related to these outcomes. RESULTS: The mean per patient hospital cost was £3866 with EPAT and £4194 with UC, reflecting a mean LoS of 2.9 days and 3.1 days, respectively. Costs were lower for non-opioids, Non-steroidal anti-inflammatories (NSAIDs) and opioids but slightly higher for adjuvants with EPAT than with UC. The mean per-patient opioid costs were £17.90 (EPAT) and £25.80 (UC). Mean per patient costs of all medication were £36 (EPAT) and £40 (UC).Complex pain intervention costs were £117 with EPAT per patient and £90 with UC. Overall mean cost per patient was £4018.3 (95% CI 3698.9 to 4337.8) with EPAT and £4323.8 (95% CI 4060.0 to 4587.7) with UC. CONCLUSIONS: EPAT facilitated personalised medicine and may result in less opioids, more specific treatments, improved pain outcomes and cost savings.
Asunto(s)
Dolor en Cáncer , Costos de la Atención en Salud , Humanos , Analgésicos Opioides/uso terapéutico , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/terapia , Hospitalización , Tiempo de Internación , Manejo del Dolor , Dimensión del DolorRESUMEN
BACKGROUND: Growing concerns about opioid use disorder (OUD) and the resulting decrease in opioid availability for patients with cancer pain highlight the need for reliable screening tools to identify the subset of patients at increased risk for aberrant opioid use. Our study examines the utility of Current Opioid Misuse Measure (COMM) recommended by the NCCN Clinical Practice Guidelines in Oncology for Adult Cancer Pain. PATIENTS AND METHODS: We analyzed prospectively collected patient-reported outcomes of 444 consecutive patients with cancer seen in pain clinics of a cancer center at 2 time points within 100 days. The relationship of COMM to other OUD screening tools, pain, opioid doses, patient demographics, and mortality was examined using univariate and multivariable logistic regression. We also examined individual items of COMM for face validity. RESULTS: Among 444 patients who completed pain surveys at 2 time points, 157 (35.4%) did not complete COMM surveys. Using a COMM cutoff of ≥13, a total of 84 patients (29.3%; 84/287) scored positive for aberrant drug use. As patients remained on opioids for 49 to 100 days, the likelihood of improving COMM score (turning from positive to negative) was 6.1 times greater than the reverse. The number of patients with COMM ≥13 was 3.8 times higher than the number of patients with CPT diagnostic codes for OUD, 5.3 times higher than those with a positive urine drug screening, and 21 times higher than those with a positive CAGE (Cut Down, Annoyed, Guilty, Eye-Opener Questionnaire) score. COMM ≥13 was not associated with pain relief response (worst pain intensity score ≥2 points on the Brief Pain Inventory), opioid doses, gender, or age. Contrary to the intended use of COMM to identify aberrant opioid use, COMM ≥13 predicted mortality: patients with COMM ≥13 were 1.9 times more likely to die within 12 months. CONCLUSIONS: Our study found that using COMM in a cancer population may significantly overestimate the risk of opioid misuse. Using COMM without modifications can create an additional barrier to cancer pain management, such as limiting appropriate opioid use.
Asunto(s)
Dolor en Cáncer , Dolor Crónico , Neoplasias , Trastornos Relacionados con Opioides , Adulto , Humanos , Analgésicos Opioides/efectos adversos , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/tratamiento farmacológico , Dolor en Cáncer/etiología , Trastornos Relacionados con Opioides/diagnóstico , Trastornos Relacionados con Opioides/epidemiología , Trastornos Relacionados con Opioides/etiología , Dolor/diagnóstico , Dolor/tratamiento farmacológico , Dolor/etiología , Encuestas y Cuestionarios , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Neoplasias/epidemiología , Dolor Crónico/inducido químicamente , Dolor Crónico/complicaciones , Dolor Crónico/tratamiento farmacológicoRESUMEN
OPINION STATEMENT: Opioid-induced neurotoxicity (OINT) is a neuropsychiatric syndrome observed with opioid therapy. The mechanism of OINT is thought to be multifactorial, and many risk factors may facilitate its development. If symptoms of OINT are seen, the prescriber should consider hydration, discontinuation of the offending opioid drug, or switching of opioid medication, or the use of some adjuvants. Multiple factors like inter- and intraindividual differences in opioid pharmacology may influence the accuracy of dose calculations for opioid switching. Experience and clinical judgment in a specialistic palliative care setting should be used and individual patient characteristics considered when applying any conversion table.
Asunto(s)
Dolor en Cáncer , Neoplasias , Humanos , Analgésicos Opioides/efectos adversos , Dolor , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/tratamiento farmacológico , Dolor en Cáncer/etiología , Metadona , Cuidados Paliativos , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológicoRESUMEN
OBJECTIVE: This study examined knowledge and practice of breakthrough cancer pain (BTcP) management among general practitioners (GPs) providing palliative care in Shanghai. DESIGN: Cross-sectional study using a self-administered questionnaire. SETTING AND PARTICIPANTS: A total of 393 GPs providing palliative care in 32 community health service centres in Shanghai were recruited by stratified cluster random sampling between 1 May and 30 June 2022. OUTCOME MEASURES: Knowledge and practice concerning BTcP management. RESULTS: A total of 375 questionnaires were collected and declared valid. The median knowledge score was 11 out of 21 points. Only 36.3% (n=136) of the participating GPs scored 11 points or more, which was categorised as good knowledge. Only 24.8% (n=93) of the GPs used Davies' adapted diagnostic algorithm as the gold standard for diagnosis. All of the GPs assessed the intensity of BTcP; however, less than a quarter of the GPs evaluated the relationship between background pain and BTcP (22.1%, n=83), the impact of BTcP on activities of daily living (24.0%, n=90), the impact of BTcP on social relationships (14.4%, n=54) and the impact of BTcP on mood (10.1%, n=38). 56.5% (n=212) of the GPs reported that they used pain tools in the assessment of BTcP. All of the GPs prescribed immediate-release morphine as rescue medication for relieving BTcP; however, 60.5% (n=227) prescribed the dose based on their personal experiences, irrespective of the basal opioid dose, and 57.3% (n=215) did not conduct dose titration after providing the initial dose. No GPs reported that they ever administered interventional treatment to their patients. CONCLUSIONS: Insufficient knowledge and inappropriate behaviours in BTcP diagnosis, assessment and treatment were identified. There is an urgent need to improve BTcP management among GPs providing palliative care in Shanghai.
Asunto(s)
Dolor Irruptivo , Dolor en Cáncer , Médicos Generales , Neoplasias , Humanos , Cuidados Paliativos , Estudios Transversales , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/tratamiento farmacológico , Actividades Cotidianas , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , China , Analgésicos Opioides/uso terapéutico , Dolor Irruptivo/diagnóstico , Dolor Irruptivo/tratamiento farmacológicoRESUMEN
BACKGROUND: A Spanish language computerized tool would facilitate cancer pain assessment and management for the underserved population of native Spanish speakers who do not speak or lack command of the English language. OBJECTIVE: Our aim was to identify Spanish-speaking adults' understanding and interpretation of the PAIN Report It-Spanish items and instructions as well as translation and technical issues. METHODS: In a cross-sectional study, 20 mostly monolingual Spanish-speaking adults engaged in 1.5- to 2-hour, audio-recorded cognitive interviews as they completed the multidimensional PAIN Report It-Spanish. Three bilingual researchers conducted content data analysis. RESULTS: Sixteen women and 4 men generally understood the translated text, but some had interpretation issues regarding the 0 to 10 number scale and understanding of the pain quality descriptors. Many participants found the program easy to complete, even when they had problems in some areas. Most participants welcomed the opportunity to report pain in their native language and appreciated research to help Hispanics with the management of their pain. CONCLUSION: PAIN Report It-Spanish is a valid tool to assess pain in a Spanish-speaking population. Improved orientation to the pain reporting tasks and alternate translations for several problematic/confusing Spanish words require additional study, especially among underrepresented black Hispanics and males. IMPLICATION FOR PRACTICE: Findings indicate that Spanish-speaking adults (1) easily use a body outline to report their pain location, (2) may use a 0 to 10 scale differently than other individuals, and (3) may have a limited repertoire of pain quality and pattern descriptors.
Asunto(s)
Dolor en Cáncer , Lenguaje , Neoplasias , Adulto , Femenino , Humanos , Masculino , Estudios Transversales , Hispánicos o Latinos , Neoplasias/complicaciones , Pruebas Neuropsicológicas , Dolor en Cáncer/diagnósticoRESUMEN
OBJECTIVE: Breakthrough cancer pain should be properly assessed for better-personalized treatment plan. The Breakthrough Pain Assessment Tool is a 14-item tool validated in English developed for this purpose; no French version is currently available and validated. This study aimed to translate it in French and assess the psychometric properties of a French version of the Breakthrough Pain Assessment Tool (BAT-FR). METHODS: First, translation and cross-cultural adaptation of the 14 items (9 ordinal and 5 nominal) of the original BAT tool in French language was made. Second, assessments of validity (convergent, divergent and discriminant validity), factorial structure (exploratory factor analysis) and test-retest reliability of the 9 ordinal items were done with data of 130 adult cancer patients suffering from breakthrough pain in a hospital-academic palliative care center. Test-retest reliability and responsiveness of total and dimension scores derived from these 9 items were also assessed. Acceptability of the 14 items was also assessed on the 130 patients. RESULTS: The 14 items had good content and face validity. Convergent and divergent validity, discriminant validity and test-retest reliability of the ordinal items were acceptable. Test-retest reliability and responsiveness of total and dimensions derived from ordinal items were also acceptable. The factorial structure of the ordinal items had two dimensions similar to the original version: "1-pain severity and impact" and "2-pain duration and medication". Items 2 and 8 had a low contribution to the dimension 1 they were assigned and item 14 clearly changed of dimension compared with the original tool. The acceptability of the 14 items was good. CONCLUSION: The BAT-FR has shown acceptable validity, reliability and responsiveness supporting its use for assessing breakthrough cancer pain in French-speaking populations. Its structure needs nevertheless further confirmation.
Asunto(s)
Dolor Irruptivo , Dolor en Cáncer , Neoplasias , Adulto , Humanos , Reproducibilidad de los Resultados , Dolor Irruptivo/diagnóstico , Dolor en Cáncer/diagnóstico , Encuestas y Cuestionarios , Lenguaje , Psicometría/métodos , Neoplasias/complicaciones , Comparación TransculturalRESUMEN
OBJECTIVE: This study assessed the impact of pancreatic cancer (PC) pain on associated symptoms, activities, and resource utilization from 2016 to 2020 in an online patient registry. PATIENTS AND METHODS: Responses from PC patient volunteers (N = 1978) were analyzed from online surveys in a cross-sectional study. Comparisons were performed between PC patient groups reporting, (1) the presence vs. absence of pre-diagnosis PC pain, (2) high (4-8) vs. low (0-3) pain intensity scores on an 11-point numerical rating scale (NRS), and (3) year of PC diagnosis (2010-2020). Descriptive statistics and all bivariate analyses were performed using Chi-square or Fisher's Exact tests. RESULTS: PC pain was the most frequently reported pre-diagnosis symptom (62%). Pre-diagnostic PC pain was reported more frequently by women, those with a younger age at diagnosis, and those with PC that spread to the liver and peritoneum. Those with pre-diagnostic PC pain vs. those without reported higher pain intensities (2.64 ± 2.54 vs.1.56 ± 2.01 NRS mean ± SD, respectively, P = .0039); increased frequencies of post-diagnosis symptoms of cramping after meals, feelings of indigestion, and weight loss (P = .02-.0001); and increased resource utilization in PC pain management: (ER visits N = 86 vs. N = 6, P = .018 and analgesic prescriptions, P < .03). The frequency of high pain intensity scores was not decreased over a recent 11-year span. CONCLUSIONS: PC pain continues to be a prominent PC symptom. Patients reporting pre-diagnosis PC pain experience increased GI metastasis, symptoms burden, and are often undertreated. Its mitigation may require novel treatments, more resources dedicated to ongoing pain management and surveillance to improve outcomes.
Asunto(s)
Dolor en Cáncer , Neoplasias Gastrointestinales , Neoplasias Pancreáticas , Humanos , Femenino , Estudios Transversales , Dolor , Neoplasias Pancreáticas/complicaciones , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/terapia , Cuidados Paliativos , Neoplasias Gastrointestinales/terapia , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/terapiaRESUMEN
BACKGROUND/AIM: The aim of this study was to establish an objective evaluation method for pain due to bone metastasis, based on heart rate variability (HRV). PATIENTS AND METHODS: In this prospective study, patients who underwent radiotherapy for painful bone metastases were enrolled. Pain was assessed using a numerical rating scale (NRS), and anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale (HADS). Autonomic and physical activities were evaluated by measuring HRV using a wearable device. NRS, HADS, and R-R interval (RRI) values were obtained upon starting, completing, and 3-5 weeks after radiotherapy. RESULTS: Between July 2020 and July 2021, 11 patients were enrolled. The median average NRS score was 5 (range=2-10). HADS-assessed median anxiety and depression scores were 8 (range=1-13 and 2-21). For patients with an NRS score ≥4, NRS score was significantly associated with low-frequency/high-frequency (LF/HF) component ratio (p=0.03). Heart rate during physical activity was significantly higher than resting heart rate; however, mean resting LF/HF was significantly higher than LF/HF during physical activity. During rest, excluding patients with a HADS depression score ≥7 in an NRS score 1-3, there was a trend for a positive correlation between the NRS score and the mean LF/HF (p=0.07). CONCLUSION: HRV measurements can objectively evaluate pain due to bone metastasis. However, we must consider that the effects of mental status, such as depression, on LF/HF also affect HRV in patients with cancer with mild pain.
Asunto(s)
Dolor en Cáncer , Humanos , Frecuencia Cardíaca , Estudios Prospectivos , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/etiología , Dolor/diagnóstico , Dolor/etiología , Ansiedad/diagnóstico , Ansiedad/etiologíaRESUMEN
Pain after cancer remains underestimated and undertreated. Precision medicine is a recent concept that refers to the ability to classify patients into subgroups that differ in their susceptibility to, biology, or prognosis of a particular disease, or in their response to a specific treatment, and thus to tailor treatment to the individual patient characteristics. Applying this to pain after cancer, the ability to classify post-cancer pain into the three major pain phenotypes (i.e. nociceptive, neuropathic, and nociplastic pain) and tailor pain treatment accordingly, is an emerging issue. This is especially relevant because available evidence suggests that nociplastic pain is present in an important subgroup of those patients experiencing post-cancer pain. The 2021 International Association for the Study of Pain (IASP) clinical criteria and grading system for nociplastic pain account for the need to identify and correctly classify patients according to the pain phenotype early in their treatment. These criteria are an important step towards precision pain medicine with great potential for the field of clinical oncology. Within this framework, the Cancer Pain Phenotyping (CANPPHE) Network, an international and interdisciplinary group of oncology clinicians and researchers from seven countries, applied the 2021 IASP clinical criteria for nociplastic pain to the growing population of those experiencing post-cancer pain. A manual is provided to allow clinicians to differentiate between predominant nociceptive, neuropathic, or nociplastic pain after cancer. A seven-step diagnostic approach is presented and illustrated using cases to enhance understanding and encourage effective implementation of this approach in clinical practice.
Asunto(s)
Dolor en Cáncer , Neoplasias , Humanos , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/etiología , Dolor en Cáncer/terapia , Medicina de Precisión , Dolor , Analgésicos , Neoplasias/complicacionesRESUMEN
Pain and suffering related to cancer are challenging issues that continue to deserve consideration for treatment optimization. Advances in analgesic management and control of the underlying cancer have improved symptom management, yet many patients still suffer from uncontrolled pain. Intrathecal drug delivery has an established role in the management of refractory cancer pain, but there are significant knowledge gaps in our understanding and application of this therapy. This review addresses several areas of controversy, including the importance of intrathecal catheter tip location, the necessity of an intrathecal trial and the role of intrathecal ziconotide and local anesthetics. In each area, the evidence is discussed, with an emphasis on presenting practical clinical guidance and highlighting deficiencies in our knowledge that are worthy of future investigation.
Asunto(s)
Dolor en Cáncer , Neoplasias , Dolor Intratable , Humanos , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/tratamiento farmacológico , Inyecciones Espinales , Sistemas de Liberación de Medicamentos , Dolor Intratable/diagnóstico , Dolor Intratable/tratamiento farmacológico , Dolor Intratable/etiología , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológicoRESUMEN
RESUMO A dor é um dos sintomas mais temidos por pacientes oncológicos e precisa ser considerada em sua integralidade. Com o objetivo de atender esse desafio, os cuidados paliativos previnem e aliviam o sofrimento de pacientes que enfrentam doenças que ameaçam a vida, pela identificação precoce, avaliação e intervenção correta da dor, considerando a integralidade do ser, por meio de quatro componentes da dor total: física, psíquica, social e espiritual. Para entender essa complexidade, a presente pesquisa objetiva analisar a produção científica nacional e internacional sobre dor total em pacientes oncológicos. Realizou-se uma revisão integrativa da literatura, selecionando artigos publicados em português e inglês entre 2014 e 2019, nas bases de dados da Scientific Electronic Library Online e do portal PubMed, por meio de quatro combinações de descritores e booleanos, encontrando-se 21.548 arquivos. Após a aplicação dos critérios de exclusão, foram selecionados 25 artigos. Prevaleceram os estudos em inglês, quantitativos e realizados por médicos. Eles sinalizaram que, dentre os sintomas, a dor é o mais prevalente na doença oncológica e o maior responsável por influenciar negativamente a qualidade de vida dos pacientes. Sinalizaram a dificuldade dos profissionais de saúde em diagnosticar e tratar a dor de forma multidimensional e a ausência de instrumentos e protocolos que norteiam essa avaliação. Conclui-se que, para a identificação e tratamento eficaz da dor de paciente em cuidados paliativos, ela deve ser considerada em sua integralidade. Para tal, fazem-se necessárias a capacitação de profissionais de saúde e a criação de instrumentos que os auxiliem no manejo dessa dor que se expressa de forma total.
RESUMEN El dolor es uno de los sintomas más temidos por los pacientes con cancer y debe considerarse em su totalidad. Para hacer frente a este desafio, los cuidados paliativos previenen y alivian el sufrimiento de pacientes que enfrentan enfermedades potencialmente mortales, a través de la identificación prematura, evaluación e intervención correcta del dolor, considerando la integralidad del ser, por medio de cuatro componentes del dolor total: física, psíquica, social y espiritual. La presente investigación objetiva examinar la producción científica nacional e internacional sobre dolor total en pacientes oncológicos. Se llevó a cabo una revisión integrativa de la literatura, seleccionando artículos publicados en portugués e inglés, entre 2014 y 2019, en las bases de datos de Scielo y del portal PubMed, encontrándose 21.548 archivos. Tras la aplicación de los criterios de exclusión, fueron seleccionado 25 artículos. Han prevalecido los estudios en inglés, cuantitativos y realizados por médicos. Ellos señalaron que, de entre los síntomas, el dolor es lo más prevalente en lo cancer y el mayor responsable por influenciar negativamente la calidad de vida de los pacientes. Han señalado la dificultad de los profesionales de salud en diagnosticar y tratar el dolor de forma multidimensional y la ausencia de instrumentos y protocolos que guían esa evaluación. Se concluyó que, para la identificación y tratamiento eficaz del dolor de paciente en cuidados paliativos, ella debe ser considerada en su grado completo. Se hacen necesarias la capacitación de profesionales de salud y la creación de instrumentos que los auxilien en el manejo de ese dolor que se expresa de manera total.
ABSTRACT Pain is one of the most feared symptoms by cancer patients and needs to be considered in its entirety. In order to meet this challenge, palliative care, it prevents and alleviates suffering of patients facing life-threatening illnesses, through early identification, assessment and correct intervention in pain that should be considered from the perspective of the whole being, through four components of total pain: physical, psychic, social and spiritual. To understand this complexity, this research aims to investigate the national and international scientific production about total pain in cancer patients. An integrative literature review was peformed, selecting articles published in Portuguese and English, between 2014 and 2019 in the Scientific Electronic Library Online and Pubmed portal databases, using four combinations of descriptors and booleans, with 21,548 files. After applying the exclusion criteria, 25 articles were selected. Studies in English, quantitative and performed by doctors, prevailed. They pointed that among the symptoms, pain is the most prevalent in cancer disease and the major responsible for influencing patients' quality of life negatively. They pointed out the difficulty of health professionals in diagnosing and treating pain in a multidimensional way, with few instruments and protocols that guide the assessment. The conclusion is that for the identification and effective treatment of pain in palliative care patients, the treatment must be considered in its entirety. For this, it is necessary the qualification of health professionals and the creation of instruments that help them to manage pain in its full expression.
Asunto(s)
Pacientes/psicología , Personal de Salud/educación , Dolor en Cáncer/diagnóstico , Cuidados Paliativos/psicología , Calidad de Vida/psicología , Revisión , Manejo del Dolor/enfermeríaRESUMEN
Context: Currently, short-term recurrence of pain is the biggest clinical challenge of celiac plexus neurolysis for patients with refractory abdominal cancer pain. Aim: To evaluate the analgesic effect and safety of celiac plexus neurolysis using ethanol injection combined with iodine-125 (125I) radioactive seed implantation for refractory abdominal cancer pain. Settings and Design: The study was a randomized controlled trial. Methods and Materials: About 10 patients with severe refractory abdominal cancer pain were enrolled in this study. The patients were randomly divided into group A (ethanol injection combined with 125I radioactive seed implantation, n = 5) and group B (ethanol injection alone, n = 5). The primary end point was pain relief measured by means of numerical rating scale (NRS). And the secondary end point was mean administration of analgesic drugs and the safety of the procedure. Statistical Analysis Used: Repeated measures of analysis of variance were used for statistical analysis. Results: The NRS scores were significantly reduced by 24 h postprocedure in both groups (group A: P = 0.001 and group B: P = 0.001). Group A did not show significant recurrence based on NRS scores during the follow-up period. In contrast, the NRS scores recurred significantly in group B by 1 month postprocedure (P = 0.026). The intake of analgesic drugs was significantly reduced in both the groups postprocedure (group A: P = 0.013 and group B: P = 0.013). Overall, it was significantly lower in group A than in group B (P = 0.041). No treatment-related deaths or major complications were observed. Conclusions: Celiac plexus neurolysis using ethanol injection in combination with 125I radioactive seed implantation has a longer analgesic duration than using ethanol injection alone. It could be a safe and long-lasting analgesic approach for managing refractory abdominal cancer pain.
Asunto(s)
Dolor en Cáncer , Plexo Celíaco , Neoplasias Pancreáticas , Dolor Abdominal/etiología , Dolor Abdominal/terapia , Analgésicos/farmacología , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/etiología , Dolor en Cáncer/terapia , Etanol , Humanos , Radioisótopos de Yodo , Neoplasias Pancreáticas/complicacionesRESUMEN
OBJECTIVE: This study assessed the impact of cancer-related neuropathic pain (CRNP) on patients and the importance of the patient-healthcare professional (HCP) relationship in diagnosis and management. METHODS: A quantitative online survey was conducted involving adult patients from 13 European countries who had been diagnosed with treatable cancer and experienced symptoms of peripheral neuropathy. RESULTS: Of 24,733 screened respondents, 549 eligible persons met the inclusion criteria and completed the questionnaire. Among individuals still experiencing pain, 75% rated it as 'severe' or 'moderate'. In addition, 61% reported a negative impact on day-to-day activities, and 30% said they had stopped working as a result. A third of respondents had received no diagnosis of CRNP despite reporting painful symptoms to an HCP. HCPs spending enough time discussing pain and understanding the impact on patients' lives were each associated with an increased likelihood of a formal CRNP diagnosis. Compared with individuals currently in active cancer treatment, cancer survivors were less likely to have a diagnosis of CRNP or regular pain conversations with HCPs. CONCLUSION: CRNP remains under-recognised despite its substantial impact on patients' lives. Clinical practice may be improved by strengthening patient-HCP relationships around pain discussions and increasing the focus on pain management among cancer survivors.
Asunto(s)
Dolor en Cáncer , Supervivientes de Cáncer , Neoplasias , Neuralgia , Adulto , Humanos , Encuestas y Cuestionarios , Personal de Salud , Dolor en Cáncer/diagnóstico , Dolor en Cáncer/etiología , Dolor en Cáncer/terapia , Neoplasias/complicaciones , Neoplasias/terapia , Neuralgia/diagnóstico , Neuralgia/etiología , Neuralgia/terapiaRESUMEN
BACKGROUND: Whether abstinence from smoking among cancer patients reduces cancer pain is still unclear. Opioids can act as a surrogate index for evaluating the incidence of severe cancer pain in countries where opioid abuse is infrequent. This study aimed to investigate whether changed smoking behavior after cancer diagnosis influences the incidence of severe cancer pain as determined by strong opioid use. METHODS: Using a large Japanese insurance claims database (n = 4,797,329), we selected 794,702 insured employees whose annual health checkup data could be confirmed ≥6 times between January 2009 and December 2018. We selected 591 study subjects from 3,256 employees who were diagnosed with cancer pain and had health checkup data at the year of cancer pain diagnosis. RESULTS: A significantly greater proportion of patients who continued smoking after cancer diagnosis ("current smoker", n = 133) received strong opioids (36.8%) compared with patients who had never smoked or had stopped before cancer diagnosis ("non-smoker", n = 383, 20.6%; p<0.05) but also compared with patients who had quit smoking after cancer diagnosis ("abstainer:", n = 75, 24.0%; p<0.05). In multivariable Cox proportional hazards regression analysis, abstainers had a significantly lower risk of receiving strong opioids than current smokers (hazard ratio: 0.57, 95% CI: 0.328 to 0.997). These findings were consistent across multiple sensitivity analyses. CONCLUSION: Our study demonstrated that patients who quit smoking after cancer diagnosis have a lower risk of severe cancer pain. This information adds clinical incentives for improving quality of life among those who smoked at the time of cancer diagnosis.